Phase 3 N=100 Coenzyme Q10 Phase III Trial in Gulf War Illness
Gulf War Illness · Chronic Fatigue · Ubiquinol
Primary: Veterans Short Form 36-Item Health Survey Physical Component Summary — 1.6; -1.1; 1.4; 1.1 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=511 Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis
Postmenopausal Osteoporosis
Primary: Percent Change From Baseline in Lumbar Spine BMD at Month 12 — 10.8571; 7.1361 percent change
Phase 3 N=362 Phase III Study of CG100649 in Osteoarthritis Patients
Localized Primary Osteoarthritis of Hip · Localized Primary Osteoarthritis of Knee
Primary: Change in WOMAC-Pain Subscale — 26.8; 27.9; 27.7; 24.2 units on a scale — p=0.011
Phase 3 N=778 Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine
Chronic Migraine
Primary: Change From Baseline in Mean Monthly Migraine Days Across 12-Week Treatment Period in mITT Population — -4.63; -7.13; -7.27 migraine days per month — p=0.0001
Phase 3 N=405 Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension
Drug Resistant Partial Onset Seizure
Primary: Double Blind: Cohort 2: Percent Change From Baseline in 28-day Seizure Frequency During Titration + Maintenance Period — -21.28; -10.25 Percent change — p=0.1788
Phase 3 N=75 Botulinum Toxin Versus Placebo Injections to Temporalis and Masseter Muscles
Pain, Head · Pain Syndrome · Temporomandibular Disorder
Primary: Change in Jaw Pain as Reported by Patient on Visual Analog Scale (VAS) — 58; 54; -19; -14 score on a scale — p=0.80
Phase 3 N=149 Use of 6% Hydroxyethylstarch (130/0.4) in Cardiac Surgical Patients
Postoperative Kidney Injury
Primary: Urine Neutrophil Gelatinase-associated Lipocalin (NGAL) [Time Frame: 24 Hours After Surgery] [Designated as Safety Issue: Yes] — 2.9; 4.0; 5.0; 4.7 ng/ml — p=0.15
Phase 3 N=180 Rainbow Extension Study
Retinopathy of Prematurity (ROP)
Primary: Visual Acuity (VA) of the Better-seeing Eye at the Participant's Fifth Birthday Visit - Comparison Between Treatment Arms — 66.8; 64.6; 62.1 Score on a scale
Phase 3 N=302 Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients
Plasma Cell Myeloma
Primary: Progression Free Survival (PFS) As Determined by Independent Response Committee (IRC): Primary Analysis — 19.15; NA months — p=0.0007
Phase 3 N=17,535 Clostridium Difficile Vaccine Efficacy Trial
Clostridium Difficile Infection
Primary: Number of First Primary Episodes of Clostridium Difficile Infection (CDI) (Definition 1) Follow-up After Dose 3 — 17; 25 Episodes
Phase 3 N=387 Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Agitation in Patients With Dementia of the Alzheimer's Type
Primary: Stage 1 and Stage 2: Change From Baseline in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score to Week 6 and Week 12 — 73.9; 72.3; 71.7; -10.7 units on a…
Phase 3 N=116 The Effects of Cognitive Behavioral Therapy and Transcranial Current Stimulation (tDCS) on Chronic Lower Back Pain
Chronic Low Back Pain · Opioid Use, Unspecified
Primary: Average Daily Pain — 5.41; 5.96 score on a scale
Phase 3 N=17 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure
Pediatric Heart Failure
Primary: Part 1: Pharmacokinetics of LCZ696 Analytes (Sacubitril, LBQ657, and Valsartan): Maximum Drug Concentration in Plasma (Cmax) — 523; 179; 1970; 549 nanograms per…
Phase 3 N=135 Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)
FAP · Familial Amyloid Polyneuropathy · TTR
Primary: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Related to Study Drug — 100; 96.5; 36.0; 54.1 percentage of…
Phase 3 N=11 RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)
Sjogren-Larsson Syndrome
Primary: Visual Index Ichthyosis Severity (VIIS) Scaling Score as Assessed by the Investigator in ADX-102 Treated Patients — -0.7 units on a scale